Search
Feed aggregator
Wave Clears Phase Ib/IIa Study in Huntington’s Disease, Eyes Accelerated Approval
Wave Clears Phase Ib/IIa Study in Huntington’s Disease, Eyes Accelerated Approval 6/26/2024
Teva Pays $750M to Resolve Israeli Tax Issues Going Back More Than a Decade
Teva Pays $750M to Resolve Israeli Tax Issues Going Back More Than a Decade 6/26/2024
How Pfizer, Bristol Myers Squibb and Johnson & Johnson Are Confronting Patent Cliffs
How Pfizer, Bristol Myers Squibb and Johnson & Johnson Are Confronting Patent Cliffs 6/26/2024
Sarepta’s Big DMD Approval, Alnylam’s Clinical Win and ADA Highlights
Sarepta’s Big DMD Approval, Alnylam’s Clinical Win and ADA Highlights 6/26/2024
After Full Approval, Sarepta Lays Out Its Next Moves
After Full Approval, Sarepta Lays Out Its Next Moves 6/26/2024
Opinion: Prepare Your Biopharma for the Next Pandemic, for Business and Global Good
Opinion: Prepare Your Biopharma for the Next Pandemic, for Business and Global Good 6/26/2024
5 FDA Decisions to Watch in the Second Half of 2024
5 FDA Decisions to Watch in the Second Half of 2024 6/24/2024
FDA Action Alert: Merck, Verona, AbbVie and Rocket
FDA Action Alert: Merck, Verona, AbbVie and Rocket 6/24/2024
Expanded Approval of Sarepta’s Elevidys Is Progress, But More Needed for DMD Patients
Expanded Approval of Sarepta’s Elevidys Is Progress, But More Needed for DMD Patients 6/21/2024
Zealand Deepens Weight-Loss Portfolio With Strong Phase Ib Data for GLP-1 Alternative
Zealand Deepens Weight-Loss Portfolio With Strong Phase Ib Data for GLP-1 Alternative 6/21/2024
Jazz’s Tremor Drug Candidate Flops in Phase II Study, Misses Primary Endpoint
Jazz’s Tremor Drug Candidate Flops in Phase II Study, Misses Primary Endpoint 6/21/2024
Vertex Finally Reaches Pricing Deal with England’s NHS for Cystic Fibrosis Drug
Vertex Finally Reaches Pricing Deal with England’s NHS for Cystic Fibrosis Drug 6/21/2024
Vanda Turns Down Cycle, Future Pak Offers as Proposals ‘Undervalue’ Company
Vanda Turns Down Cycle, Future Pak Offers as Proposals ‘Undervalue’ Company 6/21/2024
Tectonic Completes Reverse Merger With Avrobio, Starts Trading on Nasdaq
Tectonic Completes Reverse Merger With Avrobio, Starts Trading on Nasdaq 6/21/2024
Sarepta Wins Full Approval and Label Expansion for DMD Gene Therapy
Sarepta Wins Full Approval and Label Expansion for DMD Gene Therapy 6/21/2024
Lilly Takes More Legal Actions Over Compounded Tirzepatide, Warns About Counterfeits
Lilly Takes More Legal Actions Over Compounded Tirzepatide, Warns About Counterfeits 6/20/2024
Gilead’s Twice-Yearly Shot Shows 100% Efficacy in Phase III HIV Prevention Trial in Women
Gilead’s Twice-Yearly Shot Shows 100% Efficacy in Phase III HIV Prevention Trial in Women 6/20/2024
PTC Reports Positive Phase II Huntington’s Data, FDA Lifts Partial Clinical Hold
PTC Reports Positive Phase II Huntington’s Data, FDA Lifts Partial Clinical Hold 6/20/2024
Challenging Research Models to Improve Health Equity
Challenging Research Models to Improve Health Equity 6/20/2024
Experimental Parkinson’s Treatment Elicits Antibodies Against Toxic Protein in Phase I
Experimental Parkinson’s Treatment Elicits Antibodies Against Toxic Protein in Phase I 6/20/2024
World Pharma News
- Innovative ‘poop pills’ show promising results in clinical trials for multiple types of cancer
- Sanofi announces the signing of a share buyback mandate for up to €1 billion
- How a heart medication could unlock a new targeted approach in lymphoma
- A broken DNA repair tool accelerates aging
- AstraZeneca begins trading on the New York Stock Exchange